Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suciraslimab (SM03) in Rheumatoid Arthritis
NCT04312815Phase 3Unknown
- Sponsor
- SinoMab BioScience Limited
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of suciraslimab in rheumatoid arthritis (RA), sponsored by SinoMab BioScience Limited. Status: unknown.
02
Drugs
suciraslimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04312815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312815.